PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
Novonesis showcases biosolutions for Korean food producers at Seoul Food & Hotel 2026
Novonesis, a global biosolutions leader, will demonstrate how biosolutions can support more efficient food production while enhancing taste, texture, and nutritional quality that can provide benefits to ...
2026-06-08T    Food/Beverages   Health Care/Hospital   Trade show news 
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China
SHANGHAI , June 8, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, ...
2026-06-08T    Health Care/Hospital   Medical/Pharmaceuticals 
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
SAN DIEGO , June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global ...
2026-06-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
HONG KONG , June 8, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific ...
2026-06-08T    Health Care/Hospital   Medical/Pharmaceuticals 
OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
SHANGHAI , June 8, 2026 /PRNewswire/ -- OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") , annou nced that its proprietary GPC3-targeted autologous CAR-T therapy, ...
2026-06-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
SHANGHAI and HONG KONG , June 8, 2026 /PRNewswire/ -- Antengene Corporation Limited  ( "Antengene" , SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated ...
2026-06-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
NEW ORLEANS , June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing ...
2026-06-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Global Rise in Delayed Childbearing and Infertility Drives Demand for Cross-Border Fertility Care
Asian Case Studies Highlight How Regulation, Cost, and Access Are Shaping International Family Choices ...
2026-06-06T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and preventing post-treatment ...
2026-06-06T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Quantinuum Announces Closing of Upsized Initial Public Offering
BROOMFIELD, Colo. , June 6, 2026 /PRNewswire/ -- Quantinuum Inc. (Nasdaq: QNT) ("Quantinuum") today announced the closing of its upsized initial public offering of 28,000,000 shares of its ...
2026-06-06T    Computer/Electronics   Health Care/Hospital 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.